STAC-9

Organic compound, experimental pharmaceutical From Wikipedia, the free encyclopedia

STAC-9 is an experimental drug that was developed by GlaxoSmithKline as a small-molecule activator of the sirtuin subtype SIRT1, with potential applications in the treatment of diabetes.[1][2][3]

CAS Number
Quick facts Identifiers, CAS Number ...
STAC-9
Identifiers
  • N-pyridin-4-yl-6-[3-(trifluoromethyl)phenyl]-2,3-dihydropyrrolo[2,3-b]pyridine-1-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H15F3N4O
Molar mass384.362 g·mol−1
3D model (JSmol)
  • C1CN(C2=C1C=CC(=N2)C3=CC(=CC=C3)C(F)(F)F)C(=O)NC4=CC=NC=C4
  • InChI=1S/C20H15F3N4O/c21-20(22,23)15-3-1-2-14(12-15)17-5-4-13-8-11-27(18(13)26-17)19(28)25-16-6-9-24-10-7-16/h1-7,9-10,12H,8,11H2,(H,24,25,28)
  • Key:WFPOEJCACZIDSN-UHFFFAOYSA-N
Close

See also

References

Related Articles

Wikiwand AI